To mitigate the risks of morbidity and mortality associated with diabetes, the American Diabetes Association (ADA) strongly recommends using sodium – glucose cotransporter 2 inhibitor (SGLT2i) or glucagon-like peptide 1 receptor agonist (GLP-1RA) as part of the glucose-lowering treatment regimen for individuals with type 2 diabetes who also have established atherosclerotic cardiovascular disease (ASCVD). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.